The FDA has issued a notification about a labelling change for iron dextran injection (Dexferrum®) following reports of anaphylactic-type reactions, including fatalities after the parenteral administration of iron dextran injection (Dexferrum®). The Boxed Warning has been modified to recommend administering a test dose prior to the first therapeutic dose and observing for signs or symptoms of anaphylactic-type reactions during drug administration. Fatal reactions have even occurred even when the test dose was tolerated. Patients with a history of drug allergy or multiple drug allergies may be at increased risk of anaphylactic-type reactions. It is recommended that resuscitation equipment and personnel trained in the detection and treatment of anaphylactic-type reactions be readily available during Dexferrum administration.